Company intelligence / Profile preview
Avexa Limited
Hawthorn East, Melbourne, Victoria, Australiaavexa.com.au ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Avexa's lead drug apricitabine (ATC) showed promising Phase III safety and efficacy results for treatment-experienced HIV patients, but development was halted in 2010 after failing to attract a licensing partner. The company also had antibacterial programs and an integrase inhibitor program for HIV.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Shire Pharmaceuticals (licensing agreement for apricitabine)Valevia (antibacterial portfolio licensed in 2010)
Beyond the preview
Go deeper on Avexa Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avexa Limited.